# Study of QUAIL-100 in Pediatric and Young Adult Participants With High-Risk Hematologic Malignancies Who Have Received a Hematopoietic Stem Cell Transplantation

Source: https://onco.cc/trials/nct07573111/  
OnCo record `nct07573111` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1 trial of QUAIL-100 run by Laguna Biotherapeutics, Inc., now recruiting.

## Summary

Study of QUAIL-100 in Pediatric and Young Adult Participants With High-Risk Hematologic Malignancies Who Have Received a Hematopoietic Stem Cell Transplantation is a phase 1 interventional study registered as NCT07573111 by Laguna Biotherapeutics, Inc., with 12 participants planned, started 2026-08. Conditions recorded: Acute Leukemia and Myelodysplastic Syndrome. Interventions recorded: QUAIL-100.

## Fields

- Kind: Trial
- Status: recruiting
- Last checked: 2026-11-03
- Tags: pipeline; ctgov-ingest
- Registry id: NCT07573111
- Phase: 1
- Setting: An Open-label, First-in-Human, Single Ascending Dose Study of QUAIL-100 in Pediatric and Young Adult Subjects With High-Risk Acute Leukemias and Myelodysplastic Syndrome Who Have Received a T-cell Receptor (TCR) αβ+ T Cell/CD-19+ B Cell-Depleted Hematopoietic Stem Cell Transplantation
- Sponsor: Laguna Biotherapeutics, Inc.
- Enrolled: 12

## Sources

- ClinicalTrials.gov NCT07573111: https://clinicaltrials.gov/study/NCT07573111

## Connected records

- cancers: [Acute lymphoblastic leukaemia](https://onco.cc/cancers/all-leukemia/), [Myelodysplastic syndromes / neoplasms (MDS)](https://onco.cc/cancers/mds/)
- drugs: [QUAIL-100](https://onco.cc/drugs/quail-100/)
- companies: [Laguna Biotherapeutics](https://onco.cc/companies/laguna-biotherapeutics/)

---
JSON: https://onco.cc/api/v1/entities/nct07573111.json